• Home
  •  / Coherus BioSciences

Coherus BioSciences

OverviewSuggest Edit

Coherus BioSciences is a biopharmaceutical company that focuses on the biosimilar and immuno-oncology market. It markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor. The company also develops toripalimab, an anti-PD-1 antibody for the treatment of melanoma, urothelial cancer, and nasopharyngeal carcinoma; bevacizumab biosimilar; CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; ranibizumab biosimilar; and CHS-131, a once-daily oral drug candidate for non-alcoholic steatohepatitis and other metabolic conditions.

TypePublic
Founded2010
HQRedwood City, CA, USMap
Websitecoherus.com
Employee Ratings4.4More
View Jobs (46)

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2021)310(-2%)
Job Openings46
Revenue (FY, 2020)$475.8 M(+34%)
Share Price (Sept 2021)$15.8
Cybersecurity ratingDMore

Key People/Management at Coherus BioSciences

Dennis M. Lanfear

Dennis M. Lanfear

President, CEO & Chairman
Thomas F. Fitzpatrick

Thomas F. Fitzpatrick

Chief Legal Officer
Richard L. Hameister

Richard L. Hameister

Chief Quality Officer
Vincent R. Anicetti

Vincent R. Anicetti

Chief Operating Officer
Barbara K. Finck

Barbara K. Finck

Acting Chief Medical Officer
McDavid Stilwell

McDavid Stilwell

Chief Financial Officer
Show more

Coherus BioSciences Office Locations

Coherus BioSciences has offices in Redwood City and Camarillo
Redwood City, CA, US (HQ)
333 Twin Dolphin Dr #600
Camarillo, CA, US
1000 Avenida Acaso
Show all (2)

Coherus BioSciences Financials and Metrics

Coherus BioSciences Revenue

Coherus BioSciences's revenue was reported to be $475.82 m in FY, 2020 which is a 33.6% increase from the previous period.
USD

Revenue (Q1, 2021)

83.0m

Gross profit (Q1, 2021)

75.5m

Gross profit margin (Q1, 2021), %

91%

Net income (Q1, 2021)

(172.9m)

EBIT (Q1, 2021)

(167.4m)

Market capitalization (9-Sept-2021)

1.2b

Closing stock price (9-Sept-2021)

15.8

Cash (31-Mar-2021)

259.5m

EV

1.3b
Coherus BioSciences's current market capitalization is $1.2 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

356.1m475.8m

Revenue growth, %

34%

Cost of goods sold

17.1m37.7m

Gross profit

339.0m438.1m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

37.1m83.4m111.7m116.2m135.7m113.6m83.0m

Cost of goods sold

2.2m601.0k6.4m6.9m10.1m9.0m7.5m

Gross profit

34.9m82.8m105.2m109.3m125.5m104.6m75.5m

Gross profit Margin, %

94%99%94%94%93%92%91%
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

72.4m177.7m541.2m

Accounts Receivable

142.0m157.0m

Prepaid Expenses

83.0k5.0m5.6m

Inventories

1.7m9.8m44.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

81.5m105.9m165.1m193.3m224.6m292.5m259.5m

Accounts Receivable

46.5m77.4m89.6m167.5m172.5m160.7m140.4m

Prepaid Expenses

5.6m5.2m3.1m6.4m5.5m5.6m10.4m

Inventories

2.3m4.3m7.7m16.4m27.2m35.2m51.6m
show all
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(209.4m)89.8m132.2m

Depreciation and Amortization

3.2m3.3m2.9m

Inventories

(5.5m)(48.2m)(36.2m)

Accounts Payable

(301.0k)9.9m(9.8m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(20.0m)3.6m50.6m35.6m94.6m122.5m(172.9m)

Depreciation and Amortization

691.0k1.4m2.2m607.0k1.4m2.0m849.0k

Inventories

(6.4m)(16.7m)(31.2m)(9.6m)(25.2m)(30.1m)(11.4m)

Accounts Payable

(4.0m)4.0m(1.4m)(5.0m)(5.1m)(13.1m)203.0k
show all
USDFY, 2018

EV/EBIT

-3.2 x

EV/CFO

-4.1 x

Debt/Equity

-2.7 x

Debt/Assets

1 x

Financial Leverage

-2.6 x

P/E Ratio

(2.8)
Show all financial metrics

Coherus BioSciences Operating Metrics

FY, 2018FY, 2019FY, 2020

Patent Families

222525

Phase II Trials Products

111

Phase III Trials Products

1

Projects in R&D Pipeline

566
Show all operating metrics

Coherus BioSciences Acquisitions / Subsidiaries

Company NameDateDeal Size
InteKrinFebruary 12, 2014$5 m
Coherus Intermediate Corp
InteKrin Russia
InteKrin Therapeutics Inc.

Coherus BioSciences Revenue Breakdown

Embed Graph

Coherus BioSciences revenue breakdown by business segment: 38.0% from McKesson, 37.0% from AmeriSource-Bergen Corp, 23.0% from Cardinal and 2.0% from Other

Coherus BioSciences Cybersecurity Score

Cybersecurity ratingPremium dataset

D

66/100

Learn more about our premium products
SecurityScorecard logo

Coherus BioSciences Online and Social Media Presence

Coherus BioSciences's Trends

Embed Graph

Coherus BioSciences News and Updates

September 08, 2021

Coherus BioSciences Announces Upcoming Medical Conference Presentations

REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data will be presented September 13 at the IASLC 2021 World Conference on Lung Cancer and September 17 at th…
August 19, 2021

Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer

– Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone –
July 26, 2021

Coherus BioSciences to Report Second Quarter 2021 Financial Results on August 5th

REDWOOD CITY, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2021 financial results will be released after market close on Thursday, August 5, 2021. Starting at 5 p.m. ET, Coherus’ management team will host a c…
July 21, 2021

Coherus BioSciences Names Physician-Scientist Ildiko Csiki, M.D., Ph.D., Chair of its Scientific Advisory Board

- Csiki has over two decades of experience in research and drug development of cancer immunotherapies - - Csiki has over two decades of experience in research and drug development of cancer immunotherapies -
July 12, 2021

Coherus BioSciences Announces New Employment Inducement Grants

Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 6, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 221,500 shares of the common stock of the Company to newly hired employees wit…
July 11, 2021

Coherus BioSciences' (NASDAQ:CHRS) Shareholders Are Down 43% On Their Shares

At this point some shareholders may be questioning their investment in Coherus BioSciences, Inc. (NASDAQ:CHRS), since the last five years saw the share price fall 43%.
Show more

 Coherus BioSciences Frequently Asked Questions

  • When was Coherus BioSciences founded?

    Coherus BioSciences was founded in 2010.

  • Who are Coherus BioSciences key executives?

    Coherus BioSciences's key executives are Dennis M. Lanfear, Thomas F. Fitzpatrick and Richard L. Hameister.

  • How many employees does Coherus BioSciences have?

    Coherus BioSciences has 310 employees.

  • What is Coherus BioSciences revenue?

    Latest Coherus BioSciences annual revenue is $475.8 m.

  • What is Coherus BioSciences revenue per employee?

    Latest Coherus BioSciences revenue per employee is $1.5 m.

  • Who are Coherus BioSciences competitors?

    Competitors of Coherus BioSciences include Genentech, AstraZeneca and Pfizer.

  • Where is Coherus BioSciences headquarters?

    Coherus BioSciences headquarters is located at 333 Twin Dolphin Dr #600, Redwood City.

  • Where are Coherus BioSciences offices?

    Coherus BioSciences has offices in Redwood City and Camarillo.

  • How many offices does Coherus BioSciences have?

    Coherus BioSciences has 2 offices.